Professor Christian Brechot explains why lentiviral vectors could serve as an effective tool for treating a wide range of cancers and could be used for vaccines.

CAR T-cell therapy is one of the most celebrated achievements in cancer treatment, having proven effective at curing several hard-to-treat blood cancers, such as large B-cell lymphoma1 and B-cell precursor acute lymphoblastic leukaemia.2 These successes are not to be underplayed, but while CAR T-cell therapy has claimed the spotlight, it has cast a shadow on a lesser-known sister technology, one that is rooted in similar immunotherapy modification theory and could prove even more effective at treating a wider range of cancers. Lentiviral vectors have developed alongside CAR T-cell therapy and they are now revealing their true value as both an alternative therapy and a powerful, additional tool in treating a wider range of cancers. This article looks at the evidence for the use of lentiviral vectors as cancer treatments, dispelling the harmful and inaccurate myths that persist around the platform and revealing their wider use in vaccines and much more.

Read the full article on